AstraZeneca’s drug candidate baxdrostat lowered systolic blood pressure in a phase 3 clinical trial involving patients with uncontrolled or treatment-resistant hypertension.
In the trial, patients who received either 1 mg or 2 mg of baxdrostat once daily had a greater reduction in mean seated systolic blood pressure after 12 weeks compared with those who received a placebo, according to a July 14 news release from the drugmaker.
Participants continued their existing antihypertensive treatments during the study, the release said.
AstraZeneca said it will share data with regulators and present results from the study at the European Society of Cardiology Congress in August.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
